Immunophenotyping by flow cytometry is an integral part of the diagnosis and classification of leukemias/lymphomas. The expression of ROR1 associated with chronic B lymphocytic leukemia (CLL) is well described in the literature, both in its diagnosis and in the follow-up of minimal residual disease (MRD) research, however, there are few studies regarding the expression pattern of ROR1 in other subtypes of mature B lymphoid neoplasms. With the aim of evaluating the expression of ROR1 and associating it with the expression of other important markers for the differentiation of mature B lymphoid neoplasms (MBLN), 767 samples of cases that entered our laboratory for immunophenotyping with clinical suspicion of MBLN were studied. ROR1 expression is predominant in CD5+/CD10− neoplasms. Overall, positive ROR1 expression was observed in 461 (60.1%) cases. The CD5+/CD10− group had a significantly higher proportion of ROR1 positive samples (89.9%) and more brightly expressed ROR1 than the other groups. Our results highlight the importance of evaluating ROR1 expression in the diagnosis of MBLN to contribute to the differential diagnosis, and possibly therapy of mainly CLL, and indicate that this marker could be considered as a useful addition to immunophenotypic panels, particularly for more challenging cases.

中文翻译：

---

流式细胞仪检测成熟 B 淋巴肿瘤中 ROR1 的表达

流式细胞术免疫表型分析是白血病/淋巴瘤诊断和分类的重要组成部分。ROR1 与慢性 B 淋巴细胞白血病 (CLL) 相关的表达在文献中已有详细描述，无论是在其诊断还是在微小残留病 (MRD) 研究的随访中，然而，关于 ROR1 表达模式的研究很少。成熟 B 淋巴肿瘤其他亚型中的 ROR1。为了评估 ROR1 的表达并将其与成熟 B 淋巴肿瘤 (MBLN) 分化的其他重要标志物的表达相关联，对进入我们实验室进行免疫表型分析的 767 例临床怀疑 MBLN 的病例样本进行了研究。ROR1 表达在 CD5+/CD10− 肿瘤中占主导地位。总体而言，在 461 例 (60.1%) 病例中观察到 ROR1 阳性表达。CD5+/CD10−组的ROR1阳性样本比例显着较高（89.9%），且ROR1表达比其他组更明亮。我们的结果强调了评估 ROR1 表达在 MBLN 诊断中的重要性，有助于鉴别诊断，并可能有助于主要 CLL 的治疗，并表明该标记物可被视为免疫表型组的有用补充，特别是对于更具挑战性的病例。